To include your compound in the COVID-19 Resource Center, submit it here.

InflaRx, Kiniksa anti-inflammatory mAbs yield trend toward lower COVID-19 mortality, plus Sinopharm reports antibody readout from vaccine trial

Plus FDA revokes EUA for Chembio serological test, Ortho receives BARDA award for antibody assay

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.

After dexamethasone set a new bar for mortality reduction in COVID-19 patients this week, InflaRx and Kiniksa reported data from their anti-inflammatory mAbs showing trends toward a survival benefit.

InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday interim data showing a trend toward lower mortality in severe COVID-19 pneumonia patients treated with IFX-1 plus best supportive care vs. best supportive care alone in the Phase II portion of an adaptive Phase II/III trial. However, the company lost $1.81 (25%) to $5.39 on the readout, which showed no difference in oxygenation, the primary endpoint, between the two cohorts.

InflaRx, which noted that the treatment cohort had more patients with ≥2 comorbidities associated with mortality than the control group, said it has begun the study’s Phase III portion evaluating 28-day mortality as the primary endpoint.

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) reported in a Lancet Rheumatology article published Tuesday that none of the 13 patients treated with mavrilimumab under an expanded access protocol had died as of day 28; none of the patients had been mechanically ventilated. By contrast, the mortality rate in 26 patients who received the standard of care (SOC) was 27% (p=0.086). Additionally, all patients given the anti-CSF2RA mAb had exhibited clinical improvement by day 28 vs. 65% of those given SOC (p=0.03).

The Bermuda-based company’s Phase II/III study will test mavrilimumab for severe COVID-19 pneumonia and hyperinflammation. Kiniksa gained $0.58 to $24.21 on Wednesday, when it announced the publication.

Meanwhile, Sinopharm revealed on Tuesday Phase I/II data showing that prime-boost administration of BBIBP-CorV on days 0 and 28 led to neutralizing antibodies in all participants. Additionally, 97.6% of volunteers who received the inactivated SARS-CoV-2 vaccine on days 0 and 21, or on days 0 and 14, generated antiviral antibodies. Sinopharm, which is seeking ex-China partners for Phase III testing, did not disclose titers.

At least three other COVID-19 vaccine developers -- Moderna Inc. (NASDAQ:MRNA), Sinovac Biotech Ltd. (NASDAQ:SVA) and CanSino Biologics Inc. (HKEX:6185) -- have reported clinical data. CanSino is the only one to have revealed neutralizing titers (see “Sinovac COVID-19 Vaccine Yields Neutralizing Antibodies”).

Antibody tests

Citing concerns over accuracy, FDA has revoked Emergency Use Authorization (EUA) for DPP COVID-19 IgM/IgG System, a rapid serological test from Chembio Diagnostics Inc. (NASDAQ:CEMI) that detects IgG and IgM against SARS-CoV-2. The agency said Chembio’s data as well as an independent evaluation by the National Cancer Institute showed the assay generated more incorrect results than expected; and that the false result rate was higher than what was reflected in the authorized labeling.

Separately, Ortho Clinical Diagnostics Inc. has received a $678,000 award from Biomedical Advanced Research and Development Authority (BARDA) to continue developing its SARS-CoV-2 total and IgG antibody tests. Both tests have already been granted an EUA from FDA.

Targets

C5a - Complement 5a

CSF2RA - Granulocyte macrophage colony-stimulating factor receptor (CSF2RA) (GMR) (CD116) (GMCSFR)

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE